ARS Pharmaceuticals
SPRY
SPRY
165 hedge funds and large institutions have $752M invested in ARS Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 61 increasing their positions, 42 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
19% less capital invested
Capital invested by funds: $928M → $752M (-$176M)
26% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $3.65M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
165
Holding in Top 10
1
Calls
$2.68M
Puts
$3.65M
Top Buyers
| 1 | +$40.2M | |
| 2 | +$11.9M | |
| 3 | +$9.52M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.39M |
| 5 |
Goldman Sachs
New York
|
+$6.44M |
Top Sellers
| 1 | -$9.08M | |
| 2 | -$7.79M | |
| 3 | -$5.94M | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$5.82M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.69M |